Quarterly report pursuant to Section 13 or 15(d)

Financial Instruments (Tables)

v2.4.0.6
Financial Instruments (Tables)
6 Months Ended
Jun. 30, 2012
Financial Instruments [Abstract]  
Summary of the assets and liabilities measured at fair value on recurring basis
                                 

Fair Value Measurements at Reporting Date Using

 

 
    Total     Quoted Prices in
Active Markets
for Identical
Assets

(Level 1)
    Significant
Other
Observable
Inputs
(Level 2)
    Significant
Unobservable
Inputs

(Level 3)
 

Assets:

                               

Short-term investments

  $ 1,500     $ 1,500     $ —       $ —    

Liabilities:

                               

Current potion of liability for contingent value rights - CyDex

  $ 3,739     $ —       $ —       $ 3,739  

Liability for contingent value rights - Metabasis

    —         —         —         —    

Liability for contingent value rights - Neurogen

    500       —         —         500  

Liability for contingent value rights - CyDex

    9,913       —         —         9,913  
   

 

 

   

 

 

   

 

 

   

 

 

 

Total liabilities

  $ 14,152     $ —       $ —       $ 14,152  
   

 

 

   

 

 

   

 

 

   

 

 

 

The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2011 (in thousands):

 

                                 

Fair Value Measurements at Reporting Date Using

 

 
    Total     Quoted Prices in
Active Markets
for Identical
Assets

(Level 1)
    Significant
Other
Observable
Inputs
(Level 2)
    Significant
Unobservable
Inputs

(Level 3)
 

Assets:

                               

Short-term investments

  $ 10,000     $ 10,000     $ —       $ —    

Liabilities:

                               

Current potion of liability for contingent value rights - CyDex

  $ 6,879     $ —       $ —       $ 6,879  

Liability for contingent value rights - Metabasis

    1,068       1,068       —         —    

Liability for contingent value rights - Neurogen

    700       —         —         700  

Liability for contingent value rights - CyDex

    9,665       —         —         9,665  
   

 

 

   

 

 

   

 

 

   

 

 

 

Total liabilities

  $ 18,312     $ 1,068     $ —       $ 17,244